Can the ADO Index Be Used as a Predictor of Mortality from COVID-19 in Patients with COPD?

• Published in: International journal of chronic obstructive pulmonary disease Vol. 19; pp. 851 - 858
• Main Authors: Yazar, Esra Ertan, Gunluoglu, Gulsah, Arpinar Yigitbas, Burcu, Calikoglu, Mukadder, Gulbas, Gazi, Yılmaz Demirci, Nilgün, Sarioglu, Nurhan, Bozkus, Fulsen, Hoca, Nevin Taci, Ogan, Nalan, Tural Onur, Seda, Turan, Muzaffer Onur, Kosar, Filiz, Akpinar, Evrim Eylem, Mete, Burak, Ozturk, Can
• Format: Journal Article
• Language: English
• Published: New Zealand Dove Medical Press Limited 01.01.2024; Dove; Dove Medical Press
• Subjects: body mass index; chronic obstructive; covid-19; COVID-19 - diagnosis; eosinophils; fev1; Humans; Lung diseases, Obstructive; Medical research; Medicine, Experimental; Mortality; Original Research; Patient outcomes; pneumonia; Prognosis; pulmonary disease; Pulmonary Disease, Chronic Obstructive - diagnosis; Retrospective Studies; Risk Assessment; Severity of Illness Index; COVID-19; pneumonia; pulmonary disease; body mass index; mortality; chronic obstructive; eosinophils; FEV1
• ISSN: 1178-2005; 1176-9106; 1178-2005
• DOI: 10.2147/COPD.S440099

Several studies have shown that the risk of mortality due to COVID-19 is high in patients with COPD. However, evidence on factors predicting mortality is limited. Are there any useful markers to predict mortality in COVID-19 patients with COPD?. A total of 689 patients were included in this study from the COPET study, a national multicenter observational study investigating COPD phenotypes consisting of patients who were followed up with a spirometry-confirmed COPD diagnosis. Patients were also retrospectively examined in terms of COVID-19 and their outcomes. Among the study patients, 105 were diagnosed with PCR-positive COVID-19, and 19 of them died. Body mass index (p= 0.01) and ADO (age, dyspnoea, airflow obstruction) index (p= 0.01) were higher, whereas predicted FEV (p< 0.001) and eosinophil count (p= 0.003) were lower in patients who died of COVID-19. Each 0.755 unit increase in the ADO index increased the risk of death by 2.12 times, and each 0.007 unit increase in the eosinophil count decreased the risk of death by 1.007 times. The optimum cut-off ADO score of 3.5 was diagnostic with 94% sensitivity and 40% specificity in predicting mortality. Our study suggested that the ADO index recorded in the stable period in patients with COPD makes a modest contribution to the prediction of mortality due to COVID-19. Further studies are needed to validate the use of the ADO index in estimating mortality in both COVID-19 and other viral respiratory infections in patients with COPD.